AXTA vs SSRM

AXTA's deterministic scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. The stock trades below the growth-based intrinsic value of $48.10 but above the conservative Graham Number of $22.25, suggesting mixed valuation signals. Despite solid profitability metrics like a 21.33% ROE and consistent earnings beats, revenue is contracting YoY by 2.40%, and insider activity is bearish with recent selling. Analysts recommend a 'buy' with a $36.71 target, implying moderate upside from current levels around $33.62.

With a Piotroski F-Score of 4/9, SSRM exhibits stable financial health, though the absence of an Altman Z-Score leaves a gap in bankruptcy risk quantification. The stock is currently priced at $31.75, trading at a premium to its Graham Number ($26.82) but significantly below its growth-based Intrinsic Value ($54.58). While the company shows explosive YoY earnings growth and a very low forward P/E of 6.13, the 'Çöpler Incident' noted in the 10-K represents a critical qualitative risk. Despite a bearish technical trend score, the fundamental valuation and analyst consensus suggest strong upside potential.